Jinghua Weikang Capsule Containing Quadruple Therapy for IgAN With Helicobacter Pylori Infection

• Status: Not yet recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluate the efficacy and safety of the Jinghua Weikang Capsule (a Chinese patent medicine for peptic ulcer and gastritis) containing quadruple therapy (Jinghua Weikang Caplsule plus triple therpy) for eradicating Helicobacter pylori in IgA nephropathy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University First Hospital
• Treatments: Bismuth

Criteria

Inclusion Criteria:

• IgA nephropathy diagnosed by renal biopsy;

• Current Helicobacter pylori infection;

• Age 18-65.

Exclusion Criteria:

• ①eGFR<90ml/（min·1.73m2）-

• History of Helicobacter pylori treatment

• Present taking hormones or immunosuppressants

• Malignant tumor and high-grade intraepithelial neoplasia and severe dysplasia of gastric mucosa

• Allergy history to medicines used in the study

• History of gastric surgery

• Uncontrolled chronic diseases such as diabetes, cardiovascular and cerebrovascular diseases, respiratory diseases, mental disorders and other researchers are considered to affect treatment and assessment

• Combined with other primary or secondary nephropathy except for IgAN

• Combined with acute renal injury

• Female patients with pregnancy, lactation and planned pregnancy.